Investors in Life Science

SINTEF has developed venture funds, the latest of which is called SINTEF Venture VI Fund. It will manage a capital of some €50 million, of which EIF is investing some €20 million. This substantial investment aims to promote the creation of 10-15 new companies, leveraging SINTEF’s tradition of pioneering technological innovations. The EIF also invested in SINTEF’s previous funds – EIF invested €10 million in 2014 and increased to €15 million in 2018. Fund’s latest investments: Cartesian AS – Offers heating and cooling solutions by storing and extracting thermal energy from phase change materials. MoreScope – Provides a data-driven platform for companies and investors to use to quantify climate impact, carbon footprint and avoided emissions. Sonair – Offers a 3D ultrasonic sensor for robots. Mia Health – Offers a solution that gives individuals and companies easy and precise insight into the actual health benefits of the activity in which they are involved.

Research center in nanoelectronics. Imec is a world-leading R&D and innovation hub in nanoelectronics and digital technologies. At times, we shape the future. Founded in 1984, imec quickly made its name as the leading research hub for advanced CMOS scaling. We will continue to shape the roadmap for the semiconductor industry for years to come.

Valide.no supports researchers and entrepreneurs in commercializing innovative solutions with expertise, networking, and capital, contributing to a better world through research-based products and ideas

Birk Venture is a company based in Oslo, Norway, dedicated to transforming unique innovations and technologies into successful businesses in the healthcare sector. They focus on leveraging cutting-edge technologies in life science to meet the increasin.

Columbus is a Spanish investment management company that focuses on generating high returns through the Columbus Innvierte Life Science fund. This fund targets seed-stage investments in established private companies within the healthcare and life sciences sectors. The company boasts a robust investment team with international experience and a proven track record in identifying innovative excellence originating from Spanish academic institutions. COLUMBUS VENTURE PARTNERS, SGEIC, SA leverages its expertise in company building and financing to accelerate commercialization for its portfolio companies. Additionally, it facilitates rapid access to the vibrant UK and Boston/Cambridge biotech/pharma venture capital R&D ecosystem.

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

Asabys Partners is a venture capital firm based in Barcelona that invests broadly in human healthcare. The firm is active in the health-tech and biopharma industries, targeting investments in Spain and internationally in highly innovative and transformative technologies. Motivated by the goal of pushing the boundaries of science and medicine, Asabys Partners sources and finances the most disruptive technologies and collaborates with top internal and external talents in the industry. With an entrepreneurial spirit, the firm seeks to be involved in the building and management of its companies, considering itself not just as investors, but as partners and collaborators to its portfolio companies.

Axilium Holding was established in Gothenburg, Sweden in 2018. Empowered with significant investment experience in several fields, a wide professional network, and a strong desire to succeed, the two founders established an innovative investment company focusing on early stage Technology and Life Science companies based predominantly in Europe.

They invest in early-stage companies from seed to A-round and sometimes earlier, with initial investments typically ranging from 10-50 million SEK. Their evergreen fund structure allows them to prioritize long-term value over short-term gains. They focus on unique, scalable innovations that can have a meaningful societal impact, led by passionate founders capable of driving industry-changing ideas to fruition.

We create, accelerate and invest in deep-tech startups. Mission of Commercialization Reactor is to bring meaningful startups to the Global market and to provide a feasible opportunity for everyone – scientists, startup founders, investors and industrial corporations. We are an international platform for science commercialization

Tecnet equity is an Austrian venture capital fund investing in new technology enterprises as well as companies with innovative business ideas through venture capital. As an early-stage investor, tecnet plays an active part in the Austrian start-up landscape for many years. The support tecnet provides goes far beyond a financial investment. Withpersonal commitment, an international business network and many years of experience, tecnet support you in making your business successful.

QC·VENTURES is a Venture Capital investment platform of Q·ADVISERS that builds ad hoc investor syndicates around ideas and around a core team of experienced corporate finance professionals. QC invests in companies that have the potential for growth, disruption, and ambition to scale internationally.